Circassia ToleroMune hay fever vaccine shows efficacy in Phase II trial
The results from the trial demonstrated that the treatment reduced allergic symptoms in patients’ eyes by up to 30% more than placebo. The trial which involved around 50
HAYA Therapeutics has secured fast track designation from the US Food and Drug Administration (FDA) for its investigational therapy, HTX-001, to treat symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).